📄 DRHP FILED: Swara Baby Products has filed its draft prospectus (DRHP) with SEBI for an IPO of up to ₹1,000 crore. The company is a FirstCry-backed contract manufacturer of baby and adult hygiene products. This is a draft-stage filing — there is no date, price band or GMP yet.
By IPOMarket Editorial Team · Last reviewed: July 2026
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
Most IPO stories are about a brand you already know. Swara Baby Products is the opposite: a company few retail investors have heard of, sitting behind brands almost every Indian parent has. It is a contract manufacturer of disposable hygiene products — baby diapers, adult diapers, sanitary napkins and panty liners — and its largest shareholder is Brainbees Solutions, the listed parent of FirstCry, which owns 76.59%. In mid-2026 Swara filed its draft red herring prospectus (DRHP) with SEBI for an issue of up to ₹1,000 crore.
This review covers what the company actually does, why the FirstCry ownership matters more than the headline suggests, how the DRHP is structured, the financials and their fast growth, the market it is chasing, the awkward fact that it has no clean listed peer, and the risks a retail investor should weigh before the price band arrives.
Swara Baby Products IPO: Key Details at a Glance
| Detail | Information |
|---|---|
| Company | Swara Baby Products Ltd. |
| Business | Contract manufacturer — baby & adult diapers, sanitary napkins, panty liners |
| IPO Status | DRHP filed with SEBI (draft stage) |
| Issue Size | Up to ₹1,000 crore |
| Fresh Issue | ₹500 crore |
| Offer for Sale | Brainbees (FirstCry) offering up to about ₹300 crore |
| Promoter / Largest Shareholder | Brainbees Solutions (FirstCry) — 76.59% |
| Co-promoter | Alok Birla (Managing Director) |
| Lead Managers (BRLMs) | JM Financial, Avendus Capital |
| Manufacturing | 4 plants — Pithampur & Indore, Madhya Pradesh |
| Listed Peers | None directly comparable |
| Exchange | NSE + BSE (Mainboard), expected |
| Price Band / Date / GMP | Not announced — draft stage |
| GMP Today | Check live IPO GMP tracker → |
| Allotment Status | IPO allotment checker → |
Note: Issue size and structure are per the DRHP filed with SEBI. The per-share price band, dates and lot size are set at the RHP stage and are not yet public. Figures below are as reported in the DRHP filing; investors should verify against the official document.
What Swara Baby Products actually does
Swara is a business-to-business manufacturer, not a consumer brand. It makes disposable hygiene products that are sold under other companies' labels — the private-label and contract-manufacturing model. Its client list is the tell: Unicharm (MamyPoko), Procter & Gamble (Pampers), Kimberly-Clark (Huggies) and Kenvue are among the multinationals it produces for. When a shopper buys one of those brands, there is a chance it rolled off a Swara line.
The product range has widened fast. Swara started in 2021 as a single-product operation and now spans seven categories: baby diapers in both tape and pant styles, adult diapers in tape and pant styles, sanitary napkins and panty liners. Production runs across four plants in Pithampur and Indore, Madhya Pradesh, and the company is BIS certified.
Two recent moves signal ambition beyond pure contract work. In December 2025 Swara acquired KA Hygiene and Solis Hygiene and incorporated Swara Corp in the United States for international trade. It has also launched a diaper under FirstCry's own BabyHug brand using a reduced wood-pulp technology it describes as an India-first. Together these hint at a company trying to move up from job-work manufacturing toward owning technology and, eventually, brands.
The FirstCry backing, and why it matters
The single most important fact in this IPO is the ownership. Brainbees Solutions, which runs FirstCry, holds 76.59% of Swara and is the named promoter, alongside managing director Alok Birla, who brings more than 18 years in the hygiene industry. FirstCry itself is already listed — you can see its profile on the FirstCry (Brainbees) IPO page.
This matters in two directions. On the upside, a large, listed parent brings capital, distribution reach through FirstCry's retail and online network, and a captive channel for products like the BabyHug diaper. On the downside, it raises the question every investor should ask of a supplier-to-its-own-parent: how much of Swara's revenue depends on FirstCry, and are those sales at arm's-length prices? The DRHP's related-party disclosures are the first thing to read here.
Inside the DRHP: how the issue is structured
The draft proposes an issue of up to ₹1,000 crore, split between a ₹500 crore fresh issue and an offer-for-sale (OFS). In the OFS, promoter Brainbees is offering up to around ₹300 crore of its holding, with the remainder split across other selling shareholders per the filing. The fresh-issue proceeds go to the company; the OFS proceeds go to the selling shareholders, not to Swara.
The structure is worth pausing on. An OFS component means the IPO is partly a route for FirstCry to monetise a slice of its stake while Swara raises fresh growth capital. That is common and not a red flag by itself, but it does mean part of what retail is buying is an exit for the parent rather than money for the business. The book is being run by JM Financial and Avendus Capital.
Financials: fast growth, improving margins
The growth record is the strongest part of the story. Over FY23 to FY25, as reported in the DRHP:
| Metric | FY23 | FY25 | Change |
|---|---|---|---|
| Revenue | ₹545 Cr | ₹943 Cr | >30% CAGR |
| PAT | ₹26 Cr | ₹81 Cr | roughly tripled |
| PAT margin | 4.84% | 8.56% | +370 bps |
Revenue climbing from ₹545 crore to ₹943 crore is a compound growth rate above 30%, and profit rising from ₹26 crore to ₹81 crore means margins nearly doubled as the business scaled. For a contract manufacturer, that margin expansion from 4.84% to 8.56% is the more telling number — it suggests Swara is winning pricing power or a richer product mix rather than just adding volume at thin fixed margins.
One caution on the numbers. These figures are drawn from the DRHP filing, and at least one media report circulated a very different FY25 profit figure. Anchor on the DRHP's audited financials rather than secondary summaries, and read the reconciliation in the official document before valuing the company.
The market opportunity
The demand backdrop is genuinely favourable. India's diaper market was around $1.83 billion in 2025 and is projected to reach about $3.18 billion by 2034, a compound growth rate near 6.37%. The adult-diaper segment is growing faster still — at a double-digit rate through 2030 — as an ageing population and rising awareness expand a category that barely existed a decade ago.
Swara is positioned across both baby and adult hygiene, which matters: baby diapers are a large but competitive pool, while adult diapers and feminine hygiene are lower-penetration segments with more room to grow. A manufacturer that can supply all of them gives its MNC clients a single, scalable partner — the pitch underneath the seven-category expansion.
The peer problem: nothing to compare it to
Here is the unusual part. Swara has no clean listed peer. Most consumer names are brand owners; Swara is a multi-category contract manufacturer, a model that is not directly represented on the Indian exchanges. Its brand-owning clients and rivals — Pampers, MamyPoko, Huggies and Nobel Hygiene — compete in the end market, but none is a like-for-like comparison for a business-to-business producer.
That makes valuation harder than usual. Without a peer multiple to anchor against, the price band will lean on Swara's own growth and margins, and investors will have to decide whether a contract manufacturer deserves a brand-like multiple or a manufacturer-like one. The gap between those two framings is wide, and it is where the IPO will be won or lost on price.
Risks investors should weigh
- Customer and related-party concentration. With FirstCry owning 76.59% and the client base concentrated among a handful of MNCs, a lot rides on a few relationships. The share of revenue flowing through FirstCry, and whether it is at arm's length, is the key disclosure to check.
- Contract-manufacturer economics. Margins have improved, but private-label manufacturing is structurally lower-margin and more price-sensitive than brand ownership. Client bargaining power is real.
- Dependence on MNC clients. Losing or being de-prioritised by a Unicharm, P&G or Kimberly-Clark would hit volumes hard, and those decisions sit outside Swara's control.
- The OFS is a partial parent exit. Part of the issue lets FirstCry cash out a slice of its stake rather than funding the business.
- Integration and expansion risk. The KA Hygiene / Solis Hygiene acquisitions and the US subsidiary are recent and unproven; scaling them is execution risk on top of the core business.
- No peer benchmark. The absence of a comparable listed company makes the eventual valuation harder to sanity-check.
What investors should watch
Swara is a fast-growing, profitable manufacturer riding a real demand wave, with a large listed parent and a widening product range. That is a real foundation. The hesitations are about dependence and price: a business this tied to FirstCry and to a few MNC clients needs its related-party and customer-concentration disclosures read closely, and a contract manufacturer with no listed peer needs a price band that reflects manufacturer economics, not brand economics.
A sensible approach once the RHP and price band are out:
- Read the DRHP's related-party and customer-concentration sections first. They determine how much of the growth is genuinely independent of FirstCry.
- Judge the valuation on manufacturer margins, not on the consumer-brand comparisons the marketing may invite. An 8.56% net margin is good for the model, but it is still a manufacturing margin.
- Watch whether the growth run-rate holds beyond FY25, and how the new acquisitions and the US subsidiary contribute.
- Size it conservatively. A niche, single-relationship-heavy manufacturer is a satellite position, not a core holding.
- Verify your application with the IPO allotment checker after subscription.
For context on the broader 2026 pipeline, see our review of the OYO / PRISM IPO, another marquee name working through the SEBI process this year. Track the live GMP tracker and subscription data once Swara's issue opens, and read the RHP before deciding.
How to apply for the Swara Baby Products IPO
Once the issue opens for subscription, you can apply through any SEBI-registered broker:
- Zerodha →: IPO module in Console
- Upstox →: Discover → IPO
- Angel One →: IPO section
- Groww →: IPO discovery
If you do not have a demat account, open a free demat account before the issue opens. Track your applications with our IPO portfolio tracker, and watch upcoming IPOs in 2026 for the confirmed subscription dates.
Frequently asked questions
What does Swara Baby Products do? Swara is a contract manufacturer of disposable hygiene products — baby diapers (tape and pant), adult diapers (tape and pant), sanitary napkins and panty liners. It makes these on a private-label basis for multinationals including Unicharm, P&G, Kimberly-Clark and Kenvue, and runs four plants in Madhya Pradesh. It grew from a single product in 2021 to seven categories today.
Who owns Swara Baby Products? Brainbees Solutions, the listed parent of FirstCry, owns 76.59% and is the promoter, alongside managing director Alok Birla. That makes the FirstCry relationship central to the investment case.
How big is the Swara IPO? The DRHP proposes an issue of up to ₹1,000 crore — a ₹500 crore fresh issue plus an offer-for-sale in which Brainbees is offering up to about ₹300 crore of its stake. The lead managers are JM Financial and Avendus Capital. Dates and price band are not yet announced.
Is Swara Baby Products profitable? Yes. Per the DRHP, revenue rose from ₹545 crore in FY23 to ₹943 crore in FY25, and net profit from ₹26 crore to ₹81 crore, with the net margin improving from 4.84% to 8.56%. Investors should verify these against the official filing.
Does Swara have a listed competitor to compare it to? No direct one. It is a multi-category contract manufacturer, a model not cleanly represented on the Indian exchanges. Its clients and end-market rivals — Pampers, MamyPoko, Huggies and Nobel Hygiene — are brand owners, not like-for-like comparisons, which makes valuing the IPO harder.
When is the Swara Baby Products IPO date? There is no date yet. The company has filed its DRHP with SEBI; the subscription dates, price band and GMP come at the RHP stage. Track upcoming IPOs for confirmation.
Last reviewed: July 2026 by ipomarket.in Editorial Team. We update this article as Swara Baby Products moves from its DRHP filing toward a price band and listing. Bookmark this page or subscribe to IPO alerts.